CT-P16 3.1

Research code: CT-P16 3.1
Research name: Randomised double-blind, parallel-group, active-controlled phase 3 research to compare the efficacy and safety of CT-P16 and the EU-approved drug Avastin as first-line treatment of metastatic or recurrent non-squamous non-small cell lung cancer.
Indication: lung cancer
Principal researcher: Ewa Chmielowska, MD, PhD